PER® Winter Lung Cancer Conference | Conference

Novel Agents Emerging for Lesser-Known Targets in NSCLC

March 13th 2018

ROS1, NTRK, MET, and HER2 are all less common molecular targets found in non–small cell lung cancer, but emerging therapeutic strategies are being explored to attack these abnormalities.

Dr. Wakelee on First-Line Therapy for EGFR-Mutant Lung Cancer

March 12th 2018

Heather Wakelee, MD, professor of medicine, division of oncology, Stanford University, discusses first-line therapy for patients with EGFR-mutant lung cancer.

BRAF V600E Testing Necessary in NSCLC, but Experts Unsure of Optimal Setting With BRAF/MEK Combo

March 12th 2018

Upfront testing for BRAF V600E mutations is necessary for patients with non–small cell lung cancer, but if results are positive, physicians are unsure when to administer BRAF/MEK combination therapy—and they must be prepared to manage the associated adverse events.

Wakelee Discusses Debate Surrounding Osimertinib in Frontline EGFR-Mutant Lung Cancer

March 11th 2018

Heather Wakelee, MD, discusses the rapidly changing landscape of frontline EGFR tyrosine kinase inhibitors in non–small cell lung cancer.

Dr. Naidoo Discusses the Management of Immune-Related Adverse Events in Lung Cancer

March 11th 2018

Jarushka Naidoo, MBBCh, assistant professor of oncology, Johns Hopkins University, discusses advancements in the management of immune-related adverse events (irAEs) in patients with lung cancer during the 5th Annual Miami Lung Cancer Conference.

Dr. Brahmer Discusses Frontline Single-Agent Pembrolizumab in Lung Cancer

March 11th 2018

Julie R. Brahmer, MD, associate professor of oncology, co-director of the Upper Aerodigestive Department, Bloomberg Kimmel Institute for Cancer Immunotherapy, Johns Hopkins Medicine, discusses pembrolizumab (Keytruda) in the first-line treatment of non–small cell lung cancer during the 5th Annual Miami Lung Cancer Conference.

Immunotherapy Making Headway in SCLC and Mesothelioma

March 11th 2018

Immune-based therapies continue to show promising signals for patients with small cell lung cancer and mesothelioma, but better predictive biomarkers are needed to determine who is most likely to benefit.

Studies Highlight Rationale for Immunotherapy in Early-Stage and Locally Advanced NSCLC

March 11th 2018

With durvalumab (Imfinzi) being hailed as a potentially practice changing therapy in locally advanced non–small cell lung cancer, ongoing studies are seeking to determine the efficacy of immunotherapy in earlier stages of disease.

Expert Addresses Global Disparities in Lung Cancer, Efforts to Bridge the Gap

March 8th 2018

Gilberto Lopes, MD, discusses the global disparities occurring in lung cancer care and some of the steps that are being taken to better serve patients with the available and emerging therapeutic approaches.

Brahmer Highlights Latest on Immunotherapy and Other Lung Cancer Advances

March 8th 2018

Julie R. Brahmer, MD, discusses first-line immunotherapy, targeted therapies for molecularly driven tumors, and recently released guidelines for the treatment of patients with lung cancer.

Dr. Goldberg Discusses Resistance to EGFR TKI Therapy in NSCLC

March 8th 2018

Sarah B. Goldberg, MD, MPH, an assistant professor of medicine at the Yale School of Medicine and Yale Cancer Center, discusses testing for and treating resistance to EGFR tyrosine kinase inhibitor (TKI) therapy in non–small cell lung cancer.

Goldberg Gives Expert Insight on EGFR-TKI Resistant NSCLC

March 7th 2018

Sarah B. Goldberg, MD, discusses testing for and treating resistance to EGFR TKI therapy in non-small cell lung cancer.